Success Metrics

Clinical Success Rate
92.9%

Based on 13 completed trials

Completion Rate
93%(13/14)
Active Trials
0(0%)
Results Posted
15%(2 trials)
Terminated
1(7%)

Phase Distribution

Ph not_applicable
2
14%
Ph phase_2
4
29%
Ph phase_3
8
57%

Phase Distribution

0

Early Stage

4

Mid Stage

8

Late Stage

Phase Distribution14 total trials
Phase 2Efficacy & side effects
4(28.6%)
Phase 3Large-scale testing
8(57.1%)
N/ANon-phased studies
2(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

92.9%

13 of 14 finished

Non-Completion Rate

7.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(13)
Terminated(1)

Detailed Status

Completed13
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
92.9%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (28.6%)
Phase 38 (57.1%)
N/A2 (14.3%)

Trials by Status

terminated17%
completed1393%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_3

Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer

NCT00026286
completednot_applicable

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

NCT02122198
completedphase_2

Alzheimer's Disease: Therapeutic Potential of Estrogen

NCT00066157
completedphase_3

Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women

NCT00030914
completedphase_3

Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)

NCT00000559
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT00026286Phase 3

Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer

Completed
NCT02122198Not Applicable

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

Completed
NCT00066157Phase 2

Alzheimer's Disease: Therapeutic Potential of Estrogen

Completed
NCT00030914Phase 3

Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women

Completed
NCT00000559Phase 3

Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)

Completed
NCT00000466Phase 3

Postmenopausal Estrogen/Progestin Interventions (PEPI)

Completed
NCT00064025Phase 2

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

Completed
NCT00000605Phase 3

Estrogen and Graft Atherosclerosis Research Trial (EAGER)

Completed
NCT00003179Phase 2

Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer

Terminated
NCT00033358Phase 2

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

Completed
NCT00002920Phase 3

S9630, Medroxyprogesterone in Treating Women With Breast Cancer

Completed
NCT00416429Phase 3

Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Completed
NCT00004650Phase 3

Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss

Completed
NCT00006133Not Applicable

Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14